# Merck & Co. (MSD)

Source: https://nuclide.cc/companies/merck/  
Nuclide record `merck` (Company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Merck & Co. (MSD) makes Keytruda, the world's best-selling cancer drug, and is now building the next act around TROP2 ADCs and personalised vaccines.

## Summary

Pembrolizumab anchors >40 indications. Post-2028 patent-cliff strategy: sacituzumab tirumotecan (Kelun licence, >10 phase 3 trials), ifinatamab/patritumab/raludotatug deruxtecan (Daiichi Sankyo alliance, up to $22B), intismeran autogene (Moderna), zilovertamab vedotin, belzutifan, and a PD-1×VEGF bispecific (LaNova).

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Rahway, NJ
- Type: pharma
- Website: https://www.merck.com
- Ticker: MRK

## Sources

- Official website: https://www.merck.com

## Connected records

- drugs: [Lead-212 PSV359](https://nuclide.cc/drugs/pb-212-psv359/), [Olaparib](https://nuclide.cc/drugs/olaparib/), [Pembrolizumab](https://nuclide.cc/drugs/pembrolizumab/), [Temozolomide](https://nuclide.cc/drugs/temozolomide/)
- indications: [Diffuse large B-cell lymphoma](https://nuclide.cc/indications/dlbcl/), [Hepatocellular carcinoma](https://nuclide.cc/indications/hcc/), [Pheochromocytoma and paraganglioma (PPGL)](https://nuclide.cc/indications/pheochromocytoma-paraganglioma/), [Renal cell carcinoma](https://nuclide.cc/indications/rcc/), [Small-cell lung cancer](https://nuclide.cc/indications/sclc/)

---
JSON: https://nuclide.cc/api/v1/entities/merck.json